Literature DB >> 12667798

Differential incorporation of uracil DNA glycosylase UNG2 into HIV-1, HIV-2, and SIV(MAC) viral particles.

Stéphane Priet1, Jean-Marc Navarro, Nathalie Gros, Gilles Quérat, Joséphine Sire.   

Abstract

We have previously reported that the host uracil DNA glycosylase UNG2 enzyme is incorporated into HIV-1 virions via a specific association with the viral integrase (IN) domain of Gag-Pol precursor. In this study, we investigated whether UNG2 was packaged into two phylogenetically closely related primate lentiviruses, HIV-2(ROD) and SIV(MAC239). We demonstrated by GST-pull-down and coprecipitation assays that INs from HIV-1, HIV-2(ROD), and SIV(MAC239) associated with UNG2, although the interaction of UNG2 with HIV-2(ROD) IN and SIV(MAC239) IN was less strong than with HIV-1 IN. We then showed by Western blotting that highly purified HIV-2 and SIV(MAC) viral particles did not incorporate host UNG2, contrasting with the presence of UNG2 in HIV-1 viral particles. Finally, we showed that HIV-1/SIV chimeric viruses in which residues 6 to 202 of HIV-1 IN were replaced by the SIV counterpart were impaired for packaging of UNG2, indicating that the incorporation of host UNG2 into viral particles is the hallmark of the HIV-1 strain. Moreover, we found that HIV-1/SIV IN chimeric viruses were deficient for viral propagation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667798     DOI: 10.1016/s0042-6822(02)00073-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

Review 1.  Plunder and stowaways: incorporation of cellular proteins by enveloped viruses.

Authors:  Réjean Cantin; Sylvie Méthot; Michel J Tremblay
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

2.  Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.

Authors:  Shari M Kaiser; Michael Emerman
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Abundant non-canonical dUTP found in primary human macrophages drives its frequent incorporation by HIV-1 reverse transcriptase.

Authors:  Edward M Kennedy; Waaqo Daddacha; Rebecca Slater; Christina Gavegnano; Emilie Fromentin; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2011-03-31       Impact factor: 5.157

Review 4.  Retroviral reverse transcriptases.

Authors:  Alon Herschhorn; Amnon Hizi
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

5.  X4 and R5 HIV-1 have distinct post-entry requirements for uracil DNA glycosylase during infection of primary cells.

Authors:  Kate L Jones; Michael Roche; Michael P Gantier; Nasim A Begum; Tasuku Honjo; Salvatore Caradonna; Bryan R G Williams; Johnson Mak
Journal:  J Biol Chem       Date:  2010-04-06       Impact factor: 5.157

6.  Vpr overcomes macrophage-specific restriction of HIV-1 Env expression and virion production.

Authors:  Michael Mashiba; David R Collins; Valeri H Terry; Kathleen L Collins
Journal:  Cell Host Microbe       Date:  2014-11-26       Impact factor: 21.023

7.  Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.

Authors:  Bärbel Schröfelbauer; Qin Yu; Samantha G Zeitlin; Nathaniel R Landau
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 8.  Cellular kinases incorporated into HIV-1 particles: passive or active passengers?

Authors:  Charline Giroud; Nathalie Chazal; Laurence Briant
Journal:  Retrovirology       Date:  2011-09-02       Impact factor: 4.602

9.  Uracil DNA Glycosylase 2 negatively regulates HIV-1 LTR transcription.

Authors:  David Fenard; Laurent Houzet; Eric Bernard; Audrey Tupin; Sonia Brun; Marylène Mougel; Christian Devaux; Nathalie Chazal; Laurence Briant
Journal:  Nucleic Acids Res       Date:  2009-08-20       Impact factor: 16.971

Review 10.  HIV-1 Vif, APOBEC, and intrinsic immunity.

Authors:  Ritu Goila-Gaur; Klaus Strebel
Journal:  Retrovirology       Date:  2008-06-24       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.